☆ 4.6 Review

PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials

BMC CANCER (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial

Sandro Pignata et al.

Summary: This study compared carboplatin and paclitaxel with avelumab plus carboplatin and paclitaxel as first-line treatment in patients with advanced or recurrent endometrial cancer. The addition of avelumab showed potential for improving progression-free survival, but further investigation is needed.

LANCET ONCOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

Ramez N. Eskander et al.

Summary: This study collected data from 816 patients with endometrial cancer and found that adding pembrolizumab to standard chemotherapy significantly prolonged progression-free survival in advanced or recurrent endometrial cancer patients compared to chemotherapy alone.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

M. R. Mirza et al.

Summary: Dostarlimab plus carboplatin-paclitaxel significantly improved progression-free survival in patients with endometrial cancer, particularly in the mismatch repair-deficient microsatellite instability-high population.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Oncology

Cancer statistics, 2023

Rebecca L. Siegel et al.

Summary: The American Cancer Society predicts that there will be 1,958,310 new cancer cases and 609,820 cancer deaths in the United States in 2023. While incidence trends for most cancers are favorable, prostate cancer saw a significant increase of 3% annually from 2014 to 2019. However, the overall cancer death rate continues to decline due to advances in treatment, with a 33% reduction since 1991.

CA-A CANCER JOURNAL FOR CLINICIANS (2023)

Add to Collection

Article Dermatology

PD-L1 in circulating exosomes of Merkel cell carcinoma

Anais Zanella et al.

Summary: Exosomes, as potential biomarkers, have attracted interest in oncology. PD-L1 was found in circulating exosomes of MCC patients and tended to be higher in advanced disease. However, Exo-PD-L1 levels were similar to healthy donors and lower than other cancers. Changes in Exo-PD-L1 levels were not significant over the course of the disease.

EXPERIMENTAL DERMATOLOGY (2022)

Add to Collection

Article Oncology

Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

David M. O'Malley et al.

Summary: Pembrolizumab demonstrated durable antitumor activity and encouraging survival outcomes in previously treated patients with MSI-H/dMMR endometrial cancer.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

V Makker et al.

Summary: Lenvatinib plus pembrolizumab significantly prolongs progression-free survival and overall survival compared to chemotherapy in advanced endometrial cancer patients.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Obstetrics & Gynecology

The Changing Landscape of Gynecologic Cancer Mortality in the United States

Angela N. Giaquinto et al.

OBSTETRICS AND GYNECOLOGY (2022)

Add to Collection

Article Oncology

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET - a phase I, single-arm study

Ana Oaknin et al.

Summary: Dostarlimab demonstrated durable antitumor activity in patients with endometrial cancer, with a manageable safety profile.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article

Cause, Epidemiology, and Histology of Polyps and Pathways to Colorectal Cancer

Brian A. Sullivan et al.

Gastrointestinal Endoscopy Clinics of North America (2022)

Add to Collection

Review Oncology

Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine

Nicolas Huyghe et al.

Summary: ICIs are effective in Microsatellite Instability High Colorectal Cancer (MSI-H CRC), but have limited clinical benefit in Microsatellite Stable (MSS) CRC. Efforts are being made to understand the heterogeneous CRC microenvironment and find predictive biomarkers for selecting CRC patients who may respond to ICIs-based therapies. Trials are also being conducted to study new biomarkers and treatments targeting immune checkpoint molecules to improve response in MSS CRC.

CANCERS (2022)

Add to Collection

Review Oncology

Exploring immunotherapy in colorectal cancer

Junyong Weng et al.

Summary: Immunotherapy with immune checkpoint blockade has shown progress in the treatment of metastatic colorectal cancer (mCRC), although its effectiveness is limited. This review summarizes treatment strategies, discusses the mechanism and application of immune checkpoint blockade in mCRC treatment, and provides the latest research and clinical trial results.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Add to Collection

Review Medicine, Research & Experimental

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance

Sreya Bagchi et al.

Summary: This article highlights the significance of immune checkpoint inhibitors in cancer immunotherapy and the research findings on the changes in local and systemic immune cells after treatment. It emphasizes the need for understanding the requirements for an effective and safe antitumor immune response following ICI therapy.

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990?2019

Baoxia Gu et al.

Summary: The incidence of endometrial cancer (EC) has increased globally, while the mortality has decreased worldwide. There are significant differences between countries, and more efforts are needed to alleviate the disease burden of EC.

GYNECOLOGIC ONCOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Review Oncology

FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis

Shaily Arora et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

Vicky Makker et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer The Canadian Cancer Trials Group CO.26 Study

Eric X. Chen et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Oncology

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)

David S. Miller et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Review Oncology

ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach

C. Luchini et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Oncology

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer

Panagiotis A. Konstantinopoulos et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

RoB 2: a revised tool for assessing risk of bias in randomised trials

Jonathan A. C. Sterne et al.

BMJ-BRITISH MEDICAL JOURNAL (2019)

Add to Collection

Review Immunology

Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?

Francois Ghiringhelli et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

Patrick A. Ott et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Review Oncology

Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells

Zibing Wang et al.

ONCOIMMUNOLOGY (2017)

Add to Collection

Article Oncology

Landscape of Microsatellite Instability Across 39 Cancer Types

Russell Bonneville et al.

JCO PRECISION ONCOLOGY (2017)

Add to Collection

Review Oncology

Endometrial cancer: Not your grandmother's cancer

Jessica N. McAlpine et al.

CANCER (2016)

Add to Collection

Review Oncology

Microsatellite Instability as a Biomarker for PD-1 Blockade

Jonathan C. Dudley et al.

CLINICAL CANCER RESEARCH (2016)

Add to Collection

Review Oncology

The Immune Biology of Microsatellite-Unstable Cancer

Matthias Kloor et al.

TRENDS IN CANCER (2016)

Add to Collection

Meeting Abstract Oncology

PD-1, PD-L1 expression in 1599 gynecological cancers: Implications for immunotherapy

T. J. Herzog et al.

GYNECOLOGIC ONCOLOGY (2015)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Health Care Sciences & Services

The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method

Joanna IntHout et al.

BMC MEDICAL RESEARCH METHODOLOGY (2014)

Add to Collection

Article Oncology

Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy

Anke Vanderstraeten et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)

Add to Collection

Review Biochemistry & Molecular Biology

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

L. Bracci et al.

CELL DEATH AND DIFFERENTIATION (2014)

Add to Collection

Article Multidisciplinary Sciences

Integrated genomic characterization of endometrial carcinoma

Gad Getz et al.

NATURE (2013)

Add to Collection

Article Oncology

Effects of conventional therapeutic interventions on the number and function of regulatory T cells

Mario Roselli et al.

ONCOIMMUNOLOGY (2013)

Add to Collection

Article Medicine, Research & Experimental

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

W. Joost Lesterhuis et al.

JOURNAL OF CLINICAL INVESTIGATION (2011)

Add to Collection

Article Oncology

Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+T-Cell Infiltration and Survival of Patients with Cervical Carcinoma

Rezaul Karim et al.

CLINICAL CANCER RESEARCH (2009)

Add to Collection

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

Add to Collection

Article Oncology

Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel - long-term follow-up

B. Sorbe et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)

Add to Collection

Article Medicine, General & Internal

Measuring inconsistency in meta-analyses

JPT Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.